GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on August 20, 2025. The presentation will focus on the company's GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, and its development program. This event offers shareholders and the investment community a chance to engage directly with GeoVax's Chairman and CEO, David Dodd, during a live Q&A session.
The GEO-MVA vaccine has recently received favorable Scientific Advice from the European Medicines Agency, a development that could significantly expedite its regulatory approval process. This advancement positions GeoVax to play a pivotal role in global health preparedness and stockpile strategies against Mpox and smallpox. The company's MVA platform and U.S.-based manufacturing capabilities are highlighted as key factors in addressing vaccine supply diversification and biosecurity challenges.
Interested parties can register for the conference here. Questions can be submitted in advance or during the presentation, with a replay available post-event on www.EmergingGrowth.com and the Emerging Growth YouTube channel.
This presentation is crucial as it underscores the potential of GEO-MVA to fill critical gaps in pandemic readiness and vaccine accessibility, marking a significant step forward in the fight against infectious diseases. The implications of GeoVax's advancements extend beyond immediate health benefits, offering a blueprint for rapid vaccine development and regulatory approval in response to emerging global health threats.
